[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Candel Therapeutics Inc (CADL)

Candel Therapeutics Inc (CADL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 452,666
  • Shares Outstanding, K 73,247
  • Annual Sales, $ 0 K
  • Annual Income, $ -38,180 K
  • EBIT $ -48 M
  • EBITDA $ -47 M
  • 60-Month Beta -0.81
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.56

Options Overview Details

View History
  • Implied Volatility 248.62% (+5.41%)
  • Historical Volatility 88.03%
  • IV Percentile 68%
  • IV Rank 19.39%
  • IV High 970.42% on 02/17/26
  • IV Low 74.98% on 07/30/25
  • Expected Move (DTE 15) 0.98 (15.84%)
  • Put/Call Vol Ratio 1.00
  • Today's Volume 4
  • Volume Avg (30-Day) 701
  • Put/Call OI Ratio 0.35
  • Today's Open Interest 6,925
  • Open Int (30-Day) 8,920
  • Expected Range 5.19 to 7.15

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.22
  • Number of Estimates 2
  • High Estimate $-0.17
  • Low Estimate $-0.26
  • Prior Year $0.13
  • Growth Rate Est. (year over year) -269.23%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.65 +33.44%
on 03/31/26
7.66 -18.94%
on 04/20/26
+1.72 (+38.50%)
since 03/30/26
3-Month
4.44 +39.75%
on 03/30/26
7.66 -18.94%
on 04/20/26
+0.36 (+6.25%)
since 01/30/26
52-Week
4.34 +43.03%
on 05/08/25
7.66 -18.94%
on 04/20/26
+1.30 (+26.37%)
since 04/30/25

Most Recent Stories

More News
Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer

EVERSANA, a purpose-built, partner-led commercial organization, positions Candel for potential U.S. commercial launch following planned BLA submission in Q4 2026 NEEDHAM, Mass., April 29, 2026 (GLOBE...

CADL : 6.34 (+2.59%)
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEEDHAM, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological...

CADL : 6.34 (+2.59%)
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors

Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 patients with advanced non-small cell lung cancer (NSCLC) treated with aglatimagene...

CADL : 6.34 (+2.59%)
Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

Company plans to initiate a pivotal phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with progressive, metastatic, non-squamous, non-small cell lung cancer (NSCLC)...

CADL : 6.34 (+2.59%)
Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting

NEEDHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological...

CADL : 6.34 (+2.59%)
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEEDHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological...

CADL : 6.34 (+2.59%)
Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston

NEEDHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological...

CADL : 6.34 (+2.59%)
Candel Therapeutics Announces Pricing of Public Offering

NEEDHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological...

CADL : 6.34 (+2.59%)
Candel Therapeutics Announces Proposed $100 Million Public Offering

NEEDHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological...

CADL : 6.34 (+2.59%)
Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer

RTW committed $100M in U.S. launch funding, subject to U.S. Food and Drug Administration (FDA) approval of aglatimagene besadenovec (aglatimagene or CAN-2409) for intermediate- to high-risk localized prostate...

CADL : 6.34 (+2.59%)

Business Summary

Candel Therapeutics Inc. is a late clinical stage biopharmaceutical company. It involved in developing novel oncolytic viral immunotherapies. The company's product pipeline includes CAN-2409 and CAN-3110. Candel Therapeutics Inc. is based in NEEDHAM, Mass.

See More

Key Turning Points

3rd Resistance Point 6.71
2nd Resistance Point 6.60
1st Resistance Point 6.39
Last Price 6.34
1st Support Level 6.07
2nd Support Level 5.96
3rd Support Level 5.75

See More

52-Week High 7.66
Fibonacci 61.8% 6.39
Last Price 6.34
Fibonacci 50% 6.00
Fibonacci 38.2% 5.61
52-Week Low 4.34

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.